How many insider trades does FilingIQ track for APRE?

FilingIQ tracks 198 Form 4 insider transactions for APRE (Aprea Therapeutics, Inc.), covering filings from Oct 7, 2019 onwards. 0 of those are dated within the last 90 days.

Are APRE insiders net buyers or net sellers?

Across the full Form 4 history for APRE, 42 transactions (21%) were open-market purchases and 28 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does APRE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is APRE in?

Aprea Therapeutics, Inc. (APRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.19M.

APRE insider trading

NasdaqCM Healthcare

Aprea Therapeutics, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

198

Last 90 days

Buys / sells

21% / 14%

Market cap

$8.19M

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Company website: aprea.com

APRE insider activity at a glance

FilingIQ tracks 198 insider transactions for APRE in filings since Oct 7, 2019. The most recent transaction is dated Jun 16, 2026.

Across the full history, 42 open-market purchases and 28 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on APRE insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live APRE trades on FilingIQ Raw filings on SEC EDGAR

Latest APRE Form 4 filings

Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr

P Apr 1, 2026

Peters Richard

P Apr 1, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for APRE?: FilingIQ tracks 198 Form 4 insider transactions for APRE (Aprea Therapeutics, Inc.), covering filings from Oct 7, 2019 onwards. 0 of those are dated within the last 90 days.
Are APRE insiders net buyers or net sellers?: Across the full Form 4 history for APRE, 42 transactions (21%) were open-market purchases and 28 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does APRE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is APRE in?: Aprea Therapeutics, Inc. (APRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.19M.

Methodology & sources

Every APRE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.